FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics, namely to use of a combination (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-she or a pharmaceutically acceptable salt thereof and an anti-oestrogen drug selected from the group consisting of tamoxifen and fulvestrant, for the manufacture of a drug for the treatment or prevention of breast cancer, as well as to a method of treating or preventing breast cancer. Amount of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidine-1-yl)prop-2-en-1-one or its pharmaceutically acceptable salt in terms of free base is 0.001-10 mol per mole of anti-oestrogen drug.
EFFECT: above-described combination has synergistic action in treating breast cancer.
39 cl, 1 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER THERAPY USING COMPOUNDS OF 3,5-DISUBSTITUTED BENZENE ALKYNYL AND PEMBROLIZUMAB | 2020 |
|
RU2822064C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
| 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | 2013 |
|
RU2576384C1 |
| METHOD OF TREATING MALIGNANT TUMOUR | 2020 |
|
RU2816126C2 |
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINE | 2017 |
|
RU2729069C1 |
| ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | 2014 |
|
RU2664118C2 |
| INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
